FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances FibroGen raises China sale guidance to $210M, extends cash runway into 2028 as Phase II prostate cancer trial advances Post ContentfgenRead More You might also be interested in reading PSA about influencers and “experts”. August 12, 2025 In Mainstream ← Previous post Next post →